How Trends in the Pharmaceutical Industry are Impacting Healthcare
Rich Fante is currently President and Founder at RF Consulting. He most recently served as President and CEO, US at AstraZeneca from 2008 – March 2013. In this role, Rich was accountable for driving top-line growth, strengthening the company’s product pipeline through licensing and acquisition, generating transformational customer innovations, and maximizing financial contribution in the US, Canada and Latin America.
The US is the largest biopharmaceutical market in the world, and North and South America account for almost half of all global sales. As CEO, Rich led AstraZeneca to become the second largest pharmaceutical company in the US. Rich has built some of the most successful brands and brand teams in pharmaceutical marketing history, including Nexium, Crestor, Symbicort, Pulmicort, Arimidex, Seroquel and Prilosec. Prior to his President role, Rich served as Chief Operating Officer for all AstraZeneca brands in the United States. He held a number of leadership roles during more than 15 years at AstraZeneca, including Vice President–Primary Care for the gastrointestinal and respiratory franchises. Rich also held the position of Vice President, Marketing Operations, where he acted as the functional leader for all US marketing and commercial skill areas, including healthcare professional, business insight, consumer and managed markets. Before joining Astra USA in 1995, Rich worked for Lederle Laboratories. He began his career in sales and had a territory in central Massachusetts. Rich was on the Board of the National Pharmaceutical Counsel (NPC) from 2008 to 2012 and served as Chairman in 2012. NPC’s mission is to sponsor and conduct scientific analyses of the appropriate use of biopharmaceuticals and the clinical and economic value of innovation. Rich was a member of the Institute of Medicine of the National Academies of Science Roundtable on Value and Science. Rich is currently leading his own executive consulting company and serving as Senior Advisor to Vivus.
Get the latest from the world’s insight network